These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 7072211)
41. [New inotropic agents in the treatment of congestive heart failure]. Hutton I; McKillop J; Clark R; Martin W; Tweddel A Ter Arkh; 1982; 54(11):98-101. PubMed ID: 7157176 [No Abstract] [Full Text] [Related]
44. [On the advantages of the use of desacetyl-lanatoside C in cardiokinetic therapy]. De Magistris L; Menegazzo G Minerva Med; 1967 Feb; 58(13):482-8. PubMed ID: 6021619 [No Abstract] [Full Text] [Related]
46. [Perspectives for enalapril in the therapy of coronary heart disease. European Cardiology Symposium, Montreux, February 1997]. Dtsch Med Wochenschr; 1997; 122(21 Suppl Perspektiv):1-8. PubMed ID: 9439478 [No Abstract] [Full Text] [Related]
47. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine]. Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823 [TBL] [Abstract][Full Text] [Related]
48. [Therapy of ischemic and nonischemic heart failure. Current status and prospects]. Weil J; Riegger G Internist (Berl); 2002 Apr; 43 Suppl 1():S8, S11-8. PubMed ID: 11993003 [No Abstract] [Full Text] [Related]
49. Growth hormone treatment in chronic heart failure: lessons from the first 99 patients. Cicoira M; Coats AJ; Anker SD Eur Heart J; 1998 Nov; 19(11):1605-7. PubMed ID: 9857911 [No Abstract] [Full Text] [Related]
50. [Neoton (exogenic phosphocreatinine) in combined therapy of chronic cardiac failure]. Nedoshivin AO; Perepech NB Klin Med (Mosk); 1996; 74(9):45-8. PubMed ID: 9121090 [TBL] [Abstract][Full Text] [Related]
51. [Pharmacodynamic aspects of obzidan in chronic ischemic heart disease]. Zaĭtseva VI; Dorogoĭ AP Ter Arkh; 1982; 54(11):123-8. PubMed ID: 7157162 [No Abstract] [Full Text] [Related]
57. [State of several hemodynamic indices in patients with chronic circulatory insufficiency and their changes under the effects of cardiotonic therapy]. Mileshin PIa; Klykov NV Ter Arkh; 1970 Nov; 42(11):48-51. PubMed ID: 5532722 [No Abstract] [Full Text] [Related]
58. [More and more complicated combination therapy of ischemic heart disease]. Erhardt L; Herlitz J; Näslund U; Persson S Lakartidningen; 1989 Dec; 86(52):4595-7. PubMed ID: 2607868 [No Abstract] [Full Text] [Related]
59. Growth hormone and proinflammatory cytokine activation in heart failure. Just a new verse to an old sirens' song? Wollert KC; Drexler H Eur Heart J; 2003 Dec; 24(24):2164-5. PubMed ID: 14659767 [No Abstract] [Full Text] [Related]
60. [It is of importance to emphasize the optimal drug therapy in patients with chronic heart failure]. Wu XS; Hu DY Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):24-5. PubMed ID: 21418791 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]